共 39 条
- [36] Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy. BLOOD, 2008, 112 (11) : 940 - 940
- [39] Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) BLOOD, 2018, 132